Gerner, B.; Aghai-Trommeschlaeger, F.; Kraus, S.; Grigoleit, G.U.; Zimmermann, S.; Kurlbaum, M.; Klinker, H.; Isberner, N.; Scherf-Clavel, O.
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics 2022, 14, 2556.
https://doi.org/10.3390/pharmaceutics14122556
AMA Style
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics. 2022; 14(12):2556.
https://doi.org/10.3390/pharmaceutics14122556
Chicago/Turabian Style
Gerner, Bettina, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, and Oliver Scherf-Clavel.
2022. "A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients" Pharmaceutics 14, no. 12: 2556.
https://doi.org/10.3390/pharmaceutics14122556
APA Style
Gerner, B., Aghai-Trommeschlaeger, F., Kraus, S., Grigoleit, G. U., Zimmermann, S., Kurlbaum, M., Klinker, H., Isberner, N., & Scherf-Clavel, O.
(2022). A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics, 14(12), 2556.
https://doi.org/10.3390/pharmaceutics14122556